Structure Therapeutics Inc. Appoints Matthew Lang As Chief Operating Officer And General Counsel

Structure Therapeutics Inc., a clinical-stage global biopharmaceutical company developing oral small-molecule medicines for metabolic diseases such as obesity, announced the appointment of Matthew Lang, J.D., as Chief Operating Officer and General Counsel. Mr. Lang joins the company with more than fifteen years of senior leadership experience across major biopharmaceutical organizations, bringing expertise in legal strategy, corporate development, compliance, risk management, and global business operations.

Raymond Stevens, Ph.D., Chief Executive Officer of Structure Therapeutics, noted that Mr. Lang’s leadership experience and track record of guiding companies through significant growth periods will be especially important as the organization advances aleniglipron into Phase 3 development. He emphasized that Mr. Lang’s background in global operations, strategic transactions, and commercialization will support the company’s efforts to continue building a strong leadership team for its next phase of expansion.

Before joining Structure Therapeutics, Mr. Lang served as Chief Legal Officer and Secretary at Metsera, Inc., where he played a key role in the company’s acquisition by Pfizer in a transaction valued at up to $10 billion. Prior to Metsera, he held the role of Chief Business and Legal Officer at Lyell Immunopharma, Inc. and previously served in several executive positions at Myovant Sciences. During his time at Myovant, he contributed to the Phase 3 development, global approval, and commercialization of Myfembree® and Orgovyx®, two of the company’s key therapeutic products. He also served as Managing Director and General Manager of Myovant’s European operations in Basel, Switzerland, overseeing the full scope of ex-U.S. business activities.

Earlier in his career, Mr. Lang held leadership roles at Gilead Sciences and began his professional career as an attorney at Dechert LLP. He holds a B.A. in Classical Studies from Queen’s University at Kingston and a J.D. from the University of Pennsylvania Law School.

In commenting on his appointment, Mr. Lang said he is enthusiastic about joining Structure Therapeutics at a pivotal time, as the company progresses one of the most promising late-stage assets within the obesity field into Phase 3 clinical trials. He noted that the company’s mission and differentiated portfolio offer a strong platform for developing meaningful therapies for patients. 

He also expressed his commitment to strengthening operational capabilities, advancing strategic initiatives, and supporting long-term value creation. This appointment underscores Structure Therapeutics’ focus on expanding its leadership team as it accelerates development of its pipeline and prepares for the next stages of global growth.